SELLAS Life Sciences Group, Inc.
Report additional immune response data for Phase 1 MPM study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Additional immune response data is expected in the fourth quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company reported positive follow-up immune response and survival data for the Phase 1 MPM study in December 2023, meeting the fourth quarter 2023 deadline.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2024-03-28
“We reported positive topline safety and efficacy data from this study in June 2023 and positive follow-up immune response and survival data in December 2023.” ✓ confirmed on the page
Market reaction: the shares moved +15.4% against the S&P 500 over the three sessions around the disclosure (27 Mar 2024 to 2 Apr 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Immune response data for Phase 1 MPM study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002021 · Corrections policy